Protocol No. 28431754DNE3001: "A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy"

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2014 - March 1, 2019